A5003501318- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Neuropeptides and Animal Physiology
- Neuroendocrine Tumor Research Advances
- Autoimmune Bullous Skin Diseases
- Sarcoma Diagnosis and Treatment
- Microtubule and mitosis dynamics
- Cancer Diagnosis and Treatment
- Psoriasis: Treatment and Pathogenesis
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Synthesis and Biological Activity
- Lung Cancer Research Studies
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Pharmaceutical studies and practices
- Phosphodiesterase function and regulation
- Vascular Tumors and Angiosarcomas
- PARP inhibition in cancer therapy
- 14-3-3 protein interactions
- Colorectal Cancer Treatments and Studies
Hospital Jerez Puerta del Sur
2019
PharmaMar (Spain)
2011-2018
Institut Català d'Oncologia
2007
Hospital Universitario La Paz
1996
PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, affects the inflammatory microenvironment. showed strong antitumor activity in preclinical models of cisplatin-resistant epithelial ovarian cancer.Patients with platinum-resistant/refractory cancer were included two-stage, controlled, randomized (in second stage), multicenter, phase II study. Primary endpoint was overall response rate (ORR) by RECIST and/or GCIG criteria. The exploratory first...
5505 Background: PM01183 is a new anticancer agent that blocks the trans-activated transcription and induces formation of double-strand breaks in wide range cancer cell lines, including platinum-resistant (Pt-res). Methods: PRROC patients (pts) with less than 3 prior chemotherapy (CT) containing adequate organ function performance status (PS) 0-2 were included. The primary endpoint was overall response rate (ORR) (by RECIST v1.1 and/or Rustin criteria). Secondary endpoints progression free...
10517 Background: T is the first of a new class anticancer agents with transcription-targeted mechanism action. In vitro,T interferes aberrant transcription factors binding to DNA promoters in TRS. Methods: Pts advanced TRS subtypes: myxoid liposarcoma (ML), alveolar soft part sarcoma, angiomatoid fibrous histiocytoma, clear cell desmoplastic small round tumor, low grade endometrial stromal fibromyxoid chondrosarcoma and synovial stratified by performance status (0 vs 1-2) subtype (ML other...
2513 Background: PM02734 is a chemically synthesized depsipeptide with broad spectrum of activity against solid tumors in vitro (breast, colon, lung, neuroblastoma, prostate, sarcoma and thyroid) vivo melanoma); as well an acceptable non-clinical toxicology profile. Methods: Patients (n=20) metastatic or advanced were enrolled phase I, open-label, dose-escalating study to assess safety, tolerability, pharmacokinetics (PK) infused over 30 min every 21 days (d). The starting dose was 90...
e13097 Background: E is a new synthetic depsipetide with broad in vitro/in vivo antitumor activity. induces cell death through profound alterations the plasmatic membrane of tumor cells, while C targets DNA cycle independent manner. In vitro experiments showed synergistic effect between and platinum compounds different lines. Objectives: To identify maximum tolerated dose (MTD) recommended (RD) given on day (d) 1 followed by as 3-hour i.v. infusion d1 d8, every three weeks, well safety...
AbstractPlitidepsin (Aplidin®) is a novel antitumor agent, derived from the mediterranean tunicate Aplidium albicans, and currently in phase II clinical trials with evidence of activity heavily pretreated multiple myeloma, renal cell carcinoma, melanoma neuroblastoma patients. As compared to its parental compound didemnin B, plitidepsin has shown better therapeutic index less bone marrow toxicity, cardiotoxicity neurotoxicity patients more potent cytotoxic effect several tumor celllines....
<h3>Background</h3> In long-term safety studies of sunitinib, most adverse events (AE) occurred initially between the first 6 months and 1 year, remained stable or decreased in frequency over time. <h3>Purpose</h3> To analyse tolerability sunitinib real clinical practice. <h3>Material methods</h3> Retrospective descriptive observational analysis. All patients treated with from April 2010 to September 2018 were selected. Variables collected were: sex, age, diagnosis, line treatment, date...
<h3>Background and importance</h3> Secukinumab, an anti-interleukin 17 (anti-IL-17) drug, has proved to be effective in the treatment of psoriasis at its recommended dose 300 mg weeks 0, 1, 2, 3 4, then monthly during maintenance phase, according data sheet. <h3>Aim objectives</h3> To evaluate efficacy a reduced 150 patients with moderate–severe psoriasis. <h3>Material methods</h3> A retrospective observational study was conducted including treated secukinumab until March 2019. The variables...